S. 1040Introduced
Drug Competition Enhancement Act
Plain-English overview
What this bill does
Prohibits drug manufacturers from using product hopping to block generic or biosimilar competition and authorizes FTC enforcement against that conduct
Key points
- Establish rebuttable presumptions
- Prohibit product hopping
- Authorize FTC enforcement
Current status
Where it stands
Status
Introduced
Latest action
2025-04-10 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.